Skip to main content

Table 2 Clinical characteristics of subjects with eosinophilic bronchiectasis or non-eosinophilic bronchiectasis after propensity score matching

From: Eosinophilic bronchiectasis increases length and cost of hospitalization: a retrospective analysis in a hospital of southern China from 2012 to 2020

 

Non-Eos

Eos

 

N = 156

N = 156

P-value

Body mass index, kg/m2

20.4 [18.3, 23.4]

20.8 [18.2, 24.0]

0.767

Smoking status, n (%)

 Never-smokers

116 (74.4)

114 (73.1)

0.726

 Ex-smokers

25 (16.0)

27 (17.3)

0.658

 Current Smokers

15 (9.6)

15 (9.6)

0.921

Microbiology, n(%)

  

0.115

 P. aeruginosa

13 (8.3)

18 (11.5)

 

 H. influenzae

0 (0)

1 (0.6)

 

 NTM or TB

11 (7.1)

3 (1.9)

 

 Aspergillus

6 (3.8)

4 (2.6)

 

 Others

126 (80.8)

130 (83.3)

 

Etiology, n (%)

  

0.891

 Post pulmonary tuberculosis

31 (19.9)

29 (18.6)

 

 Post other infective

43 (27.5)

36 (23.1)

 

 COPD

23 (14.7)

27 (17.3)

 

 Connective tissue disease

2 (1.3)

3 (1.9)

 

 Immunodeficiency

0 (0)

1 (0.6)

 

 Others

7 (4.5)

10 (6.4)

 

 Unknown

50 (32.1)

50 (32.1)

 

Lung function

 FEV1, % predicted

56 [39, 79]

69 [45, 89]

0.071

 FVC, % predicted

68 [56, 87]

80 [64, 91]

0.046

 FEV1/FVC ratio

70 [52, 79]

72 [57, 81]

0.35

FACED score

  

0.131

 Mild (0–2)

98 (62.8)

88 (56.4)

 

 Moderate (3–4)

51 (32.7)

52 (33.3)

 

 Severe (5–7)

7 (4.5)

16 (10.3)

 

Age years

  

0.098

  ≥ 70 years

49 (31.4)

63 (40.4)

 

  < 70 years

107 (68.6)

93 (59.6)

 

FEV1% predicted

  

0.077

  < 50%

33 (21.2)

31 (14.7)

 

  ≥ 50%

122 (22.4)

123 (37.2)

 

Chronic colonization by P. aeruginosa

13 (8.3)

18 (11.5)

0.344

mMRC dyspnoea score

  

0.515

 Score I-II

136 (87.2)

132 (84.6)

 

 Score III-IV

20 (12.8)

24 (15.4)

 

Lobes affected

  

0.21

 1-2lobes

74 (47.4)

63 (40.4)

 

  > 2 lobes

82 (52.6)

93 (59.6)

 

Exacerbations in the last year

  

0.566

 0–2

124 (79.5)

128 (82.1)

 

  ≥ 3

32 (20.5)

28 (17.9)

 

Treatment

  

0.486

 ICS + LABA

7 (4.5)

6 (3.8)

 

 LABA + LAMA

2 (1.3)

0 (0)

 

 Long-term (> 2 wk) macrolides

0 (0)

0 (0)

 
  1. Abbreviations: Eos  eosinophilic bronchiectasis, Non-Eos  non-eosinophilic bronchiectasis, FEV1  forced expiratory volume in one second, FVC forced vital capacity, P. aerugonisa  Pseudomonas aeruginosa, H. influenzae Haemophilus influenza, NTM  non-tuberculous mycobacteria, TB  tuberculosis, COPD  chronic obstructive pulmonary disease, mMRC  Medical Research Council scale, ICS inhaled corticosteroids, LABA long-acting beta-agonists, LAMA long-acting muscarinic antagonists